Who Paid My Doc
Sharon Miner
Nurse Practitioner, Primary Care Wilmington, DE Nurse Practitioner
NPI 1336540657 CMS profile 10653599
1400 N Washington St, Wilmington Hospital Annex, Wilmington, DE 19801
General payments
$217
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Sharon Miner of Wilmington, DE is reported in the CMS Open Payments database as having received $217 across 2 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 41st percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $144 | 1 | |
| 2022 | General | $73 | 1 |
Beside peers
- Sharon Miner
- Nurse Practitioner, Primary Care median
- Middle half of Nurse Practitioner, Primary Care
- National median
In program year 2025, general payments to Sharon Miner were reported at $0. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.
Show as a table
| Year | Sharon Miner | Nurse Practitioner, Primary Care median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | — | — | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $0 | $137 | $39–$445 | $132 |
| 2022 | $73 | $139 | $44–$421 | $149 |
| 2023 | $0 | $163 | $53–$481 | $160 |
| 2024 | $144 | $176 | $54–$511 | $164 |
| 2025 | $0 | $169 | $51–$499 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 92 drugsPart D claims
4,148
Drug cost
$2,919,556
Branded share of claims
41.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | Brand | 381 | $1,512,447 | |
| Triumeq Abacavir/Dolutegravir/Lamivudi | Brand | 64 | $241,759 | |
| Juluca Dolutegravir/Rilpivirine | Brand | 62 | $216,603 | |
| Prezcobix Darunavir/Cobicistat | Brand | 79 | $190,012 | |
| Tivicay Dolutegravir Sodium | Brand | 68 | $152,234 | |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | Brand | 19 | $74,433 | |
| Dovato Dolutegravir Sodium/Lamivudine | Brand | 23 | $69,612 | |
| Odefsey Emtricitab/Rilpiviri/Tenof Ala | Brand | 15 | $54,400 | |
| Farxiga Dapagliflozin Propanediol | Brand | 80 | $51,051 | |
| Jardiance Empagliflozin | Brand | 55 | $42,723 |
The 10 drugs with the highest cost, of 92 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 7 billing codesPaid by Medicare
$5,025
Medicare patients
34
Services billed
134
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 74% | |
| Chronic kidney disease | 50% | |
| Diabetes | 44% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
2 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Nurse Practitioner, Primary Care in Delaware
Practitioners in the same specialty and state, ranked by reported value.
All Nurse Practitioner, Primary Care
Everyone recorded under this specialty, nationwide.
Doctors in Delaware
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.